

Doctor's Order Sheet

CARBOplatin AUC 5 - etoposide

phosphate 100 Regimen (Part I)

ARIA Protocol Name: CarbAUC5 Etoposide Phosphate 100 D1,2,3

Name:

HCN:

Date of Birth:

Adult Chemotherapy - Medical Oncology

Large Cell Neuroendocrine Lung Cancer Therapy



Weight	:	_kg	Height:		0 0415 10/2023 C	m B	ody Sur	face Area	ı (BS	A) =			_
Aller	gies:											No	o Known
	DD/MON of			Cycle Duration		ed Adn Date	ninistration of previous	on Date: _. ous cycle:	DI	D/MONT DD/MC	TH/YYA	Υ ΥΥΥΥ	
MAY P	ROCEED	WITH I	DOSES A	AS WRITTEN IF:									
•	ANC grea	ater tha	an or equ	ual to 1.5 X 10 ⁹ /	L and platelet	ts grea	ter than	or equa	l to 1	00 X 10	⁹ /L,		
	otherwise notify Medical Oncologist.												
•	LFTs and	Bilirub	in asses	sed.									
	Creatinine	e Clear	ance ass	essed.									
PREME	DICATIO	NS (FC	R HOSF	PITAL PHARMA	CY):								
□ onda	ansetron	8 mg F	PO on da	ys 1, 2 and 3									
□ dexa	amethaso	ne 8 m	g PO on	days 1, 2 and 3									
□ hydrocortisone sodium succinate 100 mg IV in 50 mL normal saline over 20 minutes on days 1, 2 and 3.													
☐ famotidine 20 mg IV in 100 mL normal saline over 15 minutes on days 1, 2 and 3. Administer concurrently with													
diphenh	nydrAMINE	E via y-	site										
□ diph	enhydrAl\	IINE 5	0 mg IV i	n 50 mL normal	saline over 1	5 minu	ites on d	ays 1, 2 a	and 3	. Admir	nister c	oncurr	ently with
famotid	line via y-s	ite											
□ Othe	er:												
PI FASE	F RFFFR	то сн	FMOTHE	RAPY LETTER	WHEN ORD	FRING	SUPPO	DRTIVE N	1FDI	CATION	IS FOF	RTHIS	PATIENT
								TH/YYYY					, , , , , , , , , , , , , , , , , , , ,
Authoriz	zed Prescr	iber's S	Signature	:				ID #: _					
Nurse's	Name: _				_ Date:	[DD/MON	TH/YYYY		Time: _			
Nurse's	Signature	:											

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Page 1 of 2 CP-0415 2023/10



Doctor's Order Sheet

CARBOplatin AUC 5 - etoposide

phosphate 100 Regimen (Part II)

ARIA Protocol Name: CarbAUC5 Etoposide Phosphate 100 D1,2,3

Name:

HCN:

Date of Birth:

Adult Chemotherapy - Medical Oncology

Large Cell Neuroendocrine Lung Cancer Therapy



CC6050 0415 10/2023

CC6050	0415 10/2023								
Weight:kg Height:	cm	Body Surface Area (I	BSA) =						
CHEMOTHERAPY (FOR HOSPITAL PHARMACY	′):								
□ CARBOplatin AUC 5 = mg									
☐ Dose modification: CARBOplatin AUC 5 -	·%	= mg							
IV in 250 mL normal saline over 30 minutes of	on day 1								
□ etoposide phosphate 100 mg/m² X BSA = mg									
□ Dose modification: etoposide phosphate 100 mg/m² X BSA mg									
IV in 500 mL normal saline over 45 minutes on days 1, 2 and 3									
Ensure patient is enrolled in Special Access Program through Health Canada in order to receive Etoposide									
Phosphate.									
PLEASE REFER TO CHEMOTHERAPY LETTER WHEN ORDERING SUPPORTIVE MEDICATIONS FOR THIS PATIENT									
Authorized Prescriber:	Date: _	DD/MONTH/YYYY	Time:						
Authorized Prescriber's Signature:		ID #:							
Nurse's Name:	Date:	DD/MONTH/YYYY	Time:						
Nurse's Signature:									

THIS IS A CONTROLLED DOCUMENT. PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION.

Page 2 of 2 CP-0415 2023/10